Literature DB >> 27582676

Topical difluprednate for treatment of serous retinal detachment and panuveitis associated with Vogt-Koyanagi-Harada disease.

Stacey Lu1, Mehran Taban1.   

Abstract

Patients with bilateral serous retinal detachments and panuveitis related to Vogt-Koyanagi-Harada disease are commonly managed with oral corticosteroids, immunosuppressive agents, and/or intravitreal injections. We present the case of a 56-year-old Hispanic man with Harada disease whose bilateral serous retinal detachments and panuveitis were treated with topical corticosteroid difluprednate alone. Functional and anatomical recoveries were assessed by fluorescein angiograms and optical coherence tomography studies over a period of 9 months. The patient's serous retinal detachments resolved, and his vision and panuveitis improved dramatically over a period of 2 weeks, after which he was placed on a drop taper and maintenance therapy for the remainder of the 9 months.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27582676      PMCID: PMC4990084          DOI: 10.5693/djo.02.2015.05.004

Source DB:  PubMed          Journal:  Digit J Ophthalmol        ISSN: 1542-8958


  7 in total

1.  Elevation of intraocular pressure in patients with uveitis treated with topical difluprednate.

Authors:  Andrea D Birnbaum; Yi Jiang; Howard H Tessler; Debra A Goldstein
Journal:  Arch Ophthalmol       Date:  2011-05

Review 2.  Current approach in the diagnosis and management of panuveitis.

Authors:  Reema Bansal; Vishali Gupta; Amod Gupta
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

3.  Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis.

Authors:  C Stephen Foster; Robert Davanzo; Thomas E Flynn; Kimberly McLeod; Roger Vogel; R Steve Crockett
Journal:  J Ocul Pharmacol Ther       Date:  2010-10       Impact factor: 2.671

4.  Subfoveal choroidal thickness after treatment of Vogt-Koyanagi-Harada disease.

Authors:  Ichiro Maruko; Tomohiro Iida; Yukinori Sugano; Hiroshi Oyamada; Tetsuju Sekiryu; Takamitsu Fujiwara; Richard F Spaide
Journal:  Retina       Date:  2011-03       Impact factor: 4.256

Review 5.  New developments in corticosteroid therapy for uveitis.

Authors:  Simon R J Taylor; Hazlita Isa; Lavnish Joshi; Sue Lightman
Journal:  Ophthalmologica       Date:  2010-08-18       Impact factor: 3.250

Review 6.  Vogt-Koyanagi-Harada syndrome.

Authors:  R S Moorthy; H Inomata; N A Rao
Journal:  Surv Ophthalmol       Date:  1995 Jan-Feb       Impact factor: 6.048

7.  Resolution of subretinal fluid with systemic corticosteroid treatment in acute Vogt-Koyanagi-Harada disease.

Authors:  Hossein Nazari; Narsing A Rao
Journal:  Br J Ophthalmol       Date:  2012-08-31       Impact factor: 4.638

  7 in total
  1 in total

1.  Risk of Elevated Intraocular Pressure With Difluprednate in Patients With Non-Infectious Uveitis.

Authors:  Mehmet Yakin; Aman Kumar; Shilpa Kodati; Leslie Jones; H Nida Sen
Journal:  Am J Ophthalmol       Date:  2022-04-02       Impact factor: 5.488

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.